JOINN Biologics Secures $80 Million in Funding to Advance Biotech and Biopharmaceutics Innovation

Xieerxin Biology, a trailblazer in biotech solutions, recently announced a remarkable funding achievement, successfully raising $80 million to drive its continued innovation in contract development and manufacturing (CDMO) services for biologics and advanced therapies. Based in the vibrant California Bay Area, JOINN Biologics—part of the JOINN Family—has established itself as a leader with over 20 years of experience in supporting drug discovery and development. The newly acquired capital will primarily focus on enhancing their core capabilities, which range from molecular assessment and cGMP clinical trial material production to upstream and downstream process development. With this significant investment, JOINN Biologics is poised to expand its operational capacity, foster cutting-edge advancements in clinical manufacturing, and further streamline processes to meet the growing demands of the biotech and biopharmaceutical industries. The funds will also facilitate state-of-the-art analytical and formulation development, ensuring their clients receive the highest quality products. In a landscape that continuously evolves, JOINN Biologics remains staunchly committed to its mission of delivering long-lasting value and innovative solutions by providing comprehensive services from early custom development to clinical trials. As the world navigates through ongoing health challenges, including the impacts of COVID-19, JOINN Biologics stands firm in prioritizing the safety and health of its community and employees while striving to meet the critical needs of patients worldwide. This funding marks an exciting new chapter for JOINN Biologics, as they continue to empower global partners and advance the future of biologic therapies. For more information about joining their mission or exploring job opportunities, visit https://www.joinnbio.com.